Literature DB >> 30077511

Inherited platelet disorders : Management of the bleeding risk.

Arnaud Dupuis1, Christian Gachet2.   

Abstract

Inherited platelet disorders are rare bleeding syndromes due to either platelet function abnormalities or thrombocytopenia which may be associated with functional defects. The haemorrhagic symptoms observed in these patients are mostly muco-cutaneous and of highly variable severity. Although 30 to 50% of the platelet disorders are still of unknown origin, the precise diagnosis of these pathologies by specialized laboratories together with haemorrhagic scores enables an assessment of the risk of bleeding in each patient. Depending on the diagnostic elements collected, an appropriate medical procedure can be proposed for each situation: scheduled or emergency surgical interventions and pregnancy follow-up. The pathologies most at risk correspond to Glanzmann's thrombasthenia, Bernard-Soulier syndrome, severe thrombocytopenia (<40,000 platelets/μL) and signalling protein abnormalities affecting the activation of GPIIb-IIIa, a membrane glycoprotein essential for platelet aggregation. For these particular patients, in whom the risk of bleeding can be increased by a factor of 40, management protocols during surgical procedures are generally based on the use of conventional platelet concentrates, for both prophylaxis and the control of active bleeding. The perinatal period in women with platelet disorders and their new-born also require special attention. Indeed, beyond unpredictable delivery haemorrhages, bleeding requiring a blood transfusion is observed after delivery in more than 50% of women with Glanzmann's thrombastenia or Bernard-Soulier syndrome.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Bleeding management; Concentré plaquettaire; Inherited platelet disorders; Pathologie plaquettaire héréditaire; Platelet concentrate; Platelet transfusion; Risque hémorragique; Thrombocytopenia; Thrombocytopénie; Thrombopathie; Thrombopathy; Transfusion plaquettaire

Mesh:

Year:  2018        PMID: 30077511     DOI: 10.1016/j.tracli.2018.07.003

Source DB:  PubMed          Journal:  Transfus Clin Biol        ISSN: 1246-7820            Impact factor:   1.406


  6 in total

1.  ETV6-related thrombocytopenia and leukemia predisposition.

Authors:  Jorge Di Paola; Christopher C Porter
Journal:  Blood       Date:  2019-06-27       Impact factor: 22.113

Review 2.  Treatment of inherited thrombocytopenias.

Authors:  Carlo L Balduini
Journal:  Haematologica       Date:  2022-06-01       Impact factor: 11.047

3.  Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial.

Authors:  Carlo Zaninetti; Paolo Gresele; Antonella Bertomoro; Catherine Klersy; Erica De Candia; Dino Veneri; Serena Barozzi; Tiziana Fierro; Maria Adele Alberelli; Valeria Musella; Patrizia Noris; Fabrizio Fabris; Carlo L Balduini; Alessandro Pecci
Journal:  Haematologica       Date:  2019-07-04       Impact factor: 9.941

Review 4.  Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia.

Authors:  José María Bastida; José Ramón Gonzalez-Porras; José Rivera; María Luisa Lozano
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

5.  Adenosine Receptor Agonists Exhibit Anti-Platelet Effects and the Potential to Overcome Resistance to P2Y12 Receptor Antagonists.

Authors:  Nina Wolska; Magdalena Boncler; Dawid Polak; Joanna Wzorek; Tomasz Przygodzki; Magdalena Gapinska; Cezary Watala; Marcin Rozalski
Journal:  Molecules       Date:  2019-12-28       Impact factor: 4.411

6.  Serum-Derived Extracellular Vesicles from African Swine Fever Virus-Infected Pigs Selectively Recruit Viral and Porcine Proteins.

Authors:  Sergio Montaner-Tarbes; Myriam Pujol; Tamara Jabbar; Philippa Hawes; Dave Chapman; Hernando Del Portillo; Lorenzo Fraile; Pedro J Sánchez-Cordón; Linda Dixon; Maria Montoya
Journal:  Viruses       Date:  2019-09-20       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.